Figure 5.

Involvement of LRP1 and P-gp in basolateral-to-apical transport of Aβ_1–40Cy5 peptide after ratio KB treatment. (A) Schematic representation of the human in vitro BBB model used for basolateral to-apical Aβ transport (green arrow) in the presence of (A) LRP1 or (B) P-gp inhibitors, respectively RAP (red ban symbol) or elacridar (orange ban symbol). (C) Aβ_1–40Cy5 or [³H]inulin basolateral-to-apical transport was performed with RAP or elacridar. The data represent the mean ± SEM obtained from at least three independent experiments relative to the control conditions, each of which was performed in triplicate (*** p < 0.001).